Results 231 to 240 of about 650,104 (308)

The Prognostic Significance of Radiographic Progression Without PSA Progression in Patients With Metastatic Hormone‐Sensitive Prostate Cancer Treated With First‐Line ARPI Therapy

The Prostate, Volume 86, Issue 8, Page 882-890, June 2026.
ABSTRACT Background Radiographic progression (RP) without prostate‐specific antigen (PSA) elevation has emerged as a clinically important pattern in the androgen receptor pathway inhibitors (ARPI) era, but its prevalence and prognostic significance in real‐world metastatic hormone‐sensitive prostate cancer (mHSPC) cohorts remain unclear.
Takeshi Tsutsumi, Shogo Yamazaki, Takuya Matsuda, Takuya Tsujino, Taizo Uchimoto, Takafumi Yanagisawa, Keiichiro Mori, Wataru Fukuokaya, Fumihiko Urabe, Masanobu Saruta, Atsuhiko Yoshizawa, Shingo Toyoda, Saizo Fujimoto, Kyosuke Nishio, Moritoshi Sakamoto, Tatsuo Fukushima, Ko Nakamura, Kazuki Nishimura, Keita Nakamori, Tomohisa Matsunaga, Yuki Yoshikawa, Ryoichi Maenosono, Kiyoshi Takahara, Teruo Inamoto, Takahiro Kimura, Kazutoshi Fujita, Kazumasa Komura, Haruhito Azuma   +27 more
wiley   +1 more source

Molecular insights into DDX3X-androgen receptor mRNA regulation via non-canonical G-quadruplex in castration-resistant prostate cancer. [PDF]

Oncogene
Zhang H, Liu TT, Wu F, Colah AN, Ricke EA, Li L, Putnam AA, Ricke WA.   +7 more
europepmc   +1 more source

Castration Resistance Accelerates Prostate Cancer Kinetics

The Prostate, Volume 86, Issue 9, Page 1021-1027, June 15, 2026.
ABSTRACT Background Prostate cancer can be an indolent disease with which patients can live for many years. Thus, an understanding of how therapy and its ensuing resistance affect prostate cancer kinetics may guide efforts to determine optimal timing of therapy initiation.
Sheila Jonnatan, Luka Cavka, Angelo M. De Marzo, Samuel R. Denmeade, Mark C. Markowski, Emmanuel S. Antonarakis, Bruce J. Trock, Catherine H. Marshall, Ravi A. Madan, David J. Einstein, Laura A. Sena   +10 more
wiley   +1 more source

Correction: SLC7A11 upregulation via AR and NEDD4L ubiquitination contributes to ferroptosis inhibition and enzalutamide resistance in castration-resistant prostate cancer. [PDF]

Cell Death Dis
Tang M, Xue L, Wang B, Jiang Z, Li P, Bu H, Zhao C, Zhang Y, Liu S, Chen X, Liu B, Meng X, Li J.   +12 more
europepmc   +1 more source

The Clinical Significance of Gallium‐68 PSMA‐11 PET‐Derived SUVmax in the Management of Metastatic Hormone‐Sensitive Prostate Cancer

The Prostate, Volume 86, Issue 9, Page 1043-1052, June 15, 2026.
ABSTRACT Purpose Previous studies have demonstrated an association between PSMA‐PET SUVmax and poorer survival outcomes in patients with mCRPC. However, limited data are available in mHSPC. We aim to investigate the relationship between baseline PSMA‐PET SUVmax and rPFS in patients with mHSPC.
Cevat İlteriş Kıkılı, Caner Kapar, Feyyaz Hazar Yağmur, Esra Arslan, Bahadır Köylü, Fatih Kemik, Buğra Han Esen, Nazan Demir, İlkay Gültürk, Murat Polat, Fatih Selçukbiricik, Deniz Tural   +11 more
wiley   +1 more source

A phase I/II trial of concurrent chemo-hormonal enzalutamide and cabazitaxel in patients with metastatic castration-resistant prostate cancer. [PDF]

Oncologist
Graff JN, Smith CEP, Sokolova AO, Qian DZ, Beer TM, Latour E, Bailey S, Kreitner D, Grivas P, Schweizer MT, Higano CS, Alumkal JJ, Vuky J, Yu EY, Cheng HH.   +14 more
europepmc   +1 more source

Impact of the Nadir Androgen Receptor Signaling Inhibitor‐Derived Integrative Response Model in Real‐World Patients With Metastatic Castration‐Sensitive Prostate Cancer

The Prostate, Volume 86, Issue 9, Page 1053-1060, June 15, 2026.
ABSTRACT Background Early deep prostate‐specific antigen (PSA) decline after the initiation of androgen receptor signaling inhibitor (ARSI) therapy is associated with favorable long‐term outcomes in metastatic castration‐sensitive prostate cancer (mCSPC).
Kazuma Yukihiro, Yohei Sekino, Keisuke Goto, Kohei Saito, Kenta Fujiyama, Yoshito Kagiyama, Yoshimasa Kurimura, Kenichiro Fukuoka, Miki Naito, Shunsuke Miyamoto, Kohei Kobatake, Hiroyuki Kitano, Akihiro Goriki, Keisuke Hieda, Nobuyuki Hinata   +14 more
wiley   +1 more source

Two Cases of Metastatic Castration-Resistant Prostate Cancer With Long-Term Survival Treated With Abiraterone. [PDF]

Clin Case Rep
Une M, Yamamoto S, Fuse H, Fujiwara R, Yonese J, Noda K.   +5 more
europepmc   +1 more source

Human Epidermal Growth Factor Receptor 2 Expression in Prostatic Carcinomas: A Systematic Review and Meta‐Analysis of a Potential Therapeutic Target

The Prostate, Volume 86, Issue 9, Page 1061-1068, June 15, 2026.
ABSTRACT Introduction The clinical relevance of HER2 expression profile in solid cancers has expanded with the evolving landscape of HER2 targeting agents. This systematic review and meta‐analysis aim to detail the prevalence of HER (over)expression in prostate cancer and identify patient/disease subgroups with enriched HER2 overexpression.
Jacky T. F. Luk, Alex H. Lin, Esther K. C. Cheung, Renald Meçani, Taulant Muka, Jana Nano, Joanna K. M. Ng, Matthew K. L. Chiu, Bryan C. W. Li, Rong Na, Joshua J. X. Li   +10 more
wiley   +1 more source

Mediation Analysis With Bayesian Nonlinear Joint Models: Evaluation of the Treatment Causal Pathways Between Tumor Growth Kinetics and Overall Survival

Statistics in Medicine, Volume 45, Issue 13-14, June 2026.
ABSTRACT Understanding the mechanisms through which anti‐cancer treatments influence survival is central to improving drug development and evaluation. In this work, we develop a Bayesian joint modeling framework for mediation analysis to quantify the extent to which tumor size dynamics mediate the effect of treatment on overall survival (OS). Our model
Georgios Kazantzidis, Francois Mercier, Virginie Rondeau   +2 more
wiley   +1 more source